| Identification of two novel mutations in the RET proto-oncogene in the same family. | None |
| Association analysis of the RET proto-oncogene with Hirschsprung disease in the Han Chinese population of southeastern China. | None |
| The RET/PTC3 oncogene activates classical NF-kappaB by stabilizing NIK. | None |
| On the use of multifactor dimensionality reduction (MDR) and classification and regression tree (CART) to identify haplotype-haplotype interactions in genetic studies. | None |
| RET proto-oncogene is associated with Parkinson_s disease | None |
| Evaluation of systemic targeting of RET oncogene-based MTC with tumor-selective peptide-tagged Ad vectors in clinical mouse models. | None |
| Single oligoarray-based detection of specific M918T mutation in RET oncogene in multiple endocrine neoplasia type 2B. | None |
| RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2. | None |
| Is the RET proto-oncogene involved in the pathogenesis of intestinal neuronal dysplasia type B?. | None |
| Predicting phenotypic severity of uncertain gene variants in the RET proto-oncogene. | None |
| [Phenotype of the C634Y mutation in the RET proto-oncogene in MEN2A: report of a family]. | None |
| Solution structure of all parallel G-quadruplex formed by the oncogene RET promoter sequence. | None |
| Chasing the ubiquitous RET proto-oncogene in South African MEN2 families--implications for the surgeon. | None |
| In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. | None |
| Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. | None |
| Study reports the coexistence of a germline intronic heterozygote variation at the MEN1 gene (IVS4+1G>T) and a germline mutation of exon 11 of RET proto-oncogene (K666M) in a large Italian family and describes clinical manifestations in the carriers. | None |
| Synergistic growth inhibition of cancer cells harboring the RET/PTC1 oncogene by staurosporine and rotenone involves enhanced cell death. | None |
| Establishing high resolution melting analysis: method validation and evaluation for c-RET proto-oncogene mutation screening. | None |
| Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein. | None |
| we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas | None |